论文部分内容阅读
美国新泽西消息:美国有12个中心开始进行一项双盲研究,目的是确定环孢菌素治疗多发性硬化症(MS)是否起作用。迄今已有160 名病人参加,但此研究的全部定额是480人,预计今年年底可以达到定额。每一个医疗中心都按照山道士制药公司(商品环孢菌素唯一的制造厂)设计的复杂方案对病人进行2年试验。慢性进行性MS患者开始时接受6mg/kg的环孢菌素,大约是通常给予移植病人的一半,在试验中必要时可调整剂量。医生根据多发性硬化学会国际联合会制定的新的残废等级标准检查病人。此标准证明病
NEW ZEALAND, USA - Twelve centers in the United States have started a double-blind study to determine if cyclosporin is effective in treating multiple sclerosis (MS). To date, 160 patients have participated, but the total quota for this study is 480 and a quota is expected by the end of this year. Each medical center conducts a 2-year trial of the patient in accordance with the complex protocol designed by Hillsborough Pharmaceuticals, the only manufacturer of cyclosporine. Chronic progressive MS patients initially receive 6 mg / kg of cyclosporin, which is about half that usually given to a transplant patient, and the dose can be adjusted as necessary in the trial. Doctors examine patients based on new disability rating criteria developed by the International Federation of Multiple Sclerosis. This standard proves ill